LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
| Revenue (TTM) | $60.26M |
| Gross Profit (TTM) | $29.13M |
| EBITDA | $-16.33M |
| Operating Margin | 12.90% |
| Return on Equity | 35.70% |
| Return on Assets | -18.70% |
| Revenue/Share (TTM) | $4.96 |
| Book Value | $1.21 |
| Price-to-Book | 4.53 |
| Price-to-Sales (TTM) | 1.11 |
| EV/Revenue | 0.936 |
| EV/EBITDA | -1.04 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 18.40% |
| Shares Outstanding | $12.29M |
| Float | $8.84M |
| % Insiders | 21.52% |
| % Institutions | 45.11% |
Volatility is currently expanding
ORLANDO, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2026 financial results will be released before market open on Tuesday, November 10, 2026.
LENSAR NASDAQ: LNSR reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarter.
10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base Climbs to 445 Systems, Driven by 30% Growth in ALLY Placements ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2026 and provided an update on key operational initiatives.
LENSAR NASDAQ: LNSR executives told investors on Thursday that the company is moving past a “transaction-related holding pattern” after the termination of its planned merger, and is now refocusing on rebuilding commercial momentum around its ALLY femtosecond laser cataract platform. Management said first-quarter results reflected that period of uncertainty, but highlighted continued growth in recurring revenue and rising procedure volumes.
LENSAR, Inc. (LNSR) Q1 2026 Earnings Call Transcript
7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2026 financial results will be released before market open on Friday, May 8, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LNSR and any ticker you trade — then tracks every position and per-strategy win rate.
